HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity.
Reynolds JG, Geretti E, Hendriks BS, Lee H, Leonard SC, Klinz SG, Noble CO, Lücker PB, Zandstra PW, Drummond DC, Olivier KJ Jr, Nielsen UB, Niyikiza C, Agresta SV, Wickham TJ.
Reynolds JG, et al. Among authors: klinz sg.
Toxicol Appl Pharmacol. 2012 Jul 1;262(1):1-10. doi: 10.1016/j.taap.2012.04.008. Epub 2012 Apr 21.
Toxicol Appl Pharmacol. 2012.
PMID: 22676972